Citations (10)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Ian Blumer, Jeremy H. Pettus & Tricia Santos Cavaiola. (2018) Fixed-ratio combination therapy for type 2 diabetes: the top ten things you should know about insulin and glucagon-like peptide-1 receptor agonist combinations. Postgraduate Medicine 130:4, pages 375-380.
Read now
Read now
Ronald M. Goldenberg & Lori Berard. (2018) Adding prandial GLP-1 receptor agonists to basal insulin: a promising option for type 2 diabetes therapy. Current Medical Research and Opinion 34:1, pages 1-10.
Read now
Read now
Neil Skolnik, Renell S. Dupree & Eric L. Johnson. (2017) iGlarLixi, a titratable once-daily fixed-ratio combination of basal insulin and lixisenatide for intensifying type 2 diabetes management for patients inadequately controlled on basal insulin with or without oral agents. Current Medical Research and Opinion 33:12, pages 2187-2194.
Read now
Read now
Articles from other publishers (7)
Tricia Santos Cavaiola, Yan Kiriakov & Timothy Reid. (2019) Primary Care Management of Patients With Type 2 Diabetes: Overcoming Inertia and Advancing Therapy With the Use of Injectables. Clinical Therapeutics 41:2, pages 352-367.
Crossref
Crossref
Ariel Zisman, Terry Dex, Michelle Roberts, Aramesh Saremi, Jason Chao & Vanita R. Aroda. (2018) Bedtime-to-Morning Glucose Difference and iGlarLixi in Type 2 Diabetes: Post Hoc Analysis of LixiLan-L. Diabetes Therapy 9:5, pages 2155-2162.
Crossref
Crossref
Debbie Hinnen & Jodi Strong. (2018) iGlarLixi: A New Once-Daily Fixed-Ratio Combination of Basal Insulin Glargine and Lixisenatide for the Management of Type 2 Diabetes. Diabetes Spectrum 31:2, pages 145-154.
Crossref
Crossref
Neil Skolnik, Debbie Hinnen, Yan Kiriakov, Melissa L. Magwire & John R. WhiteJr.Jr.. (2018) Initiating Titratable Fixed-Ratio Combinations of Basal Insulin Analogs and Glucagon-Like Peptide-1 Receptor Agonists: What You Need to Know. Clinical Diabetes 36:2, pages 174-182.
Crossref
Crossref
Jennifer Goldman & Jennifer M. Trujillo. (2017) iGlarLixi: A Fixed-Ratio Combination of Insulin Glargine 100 U/mL and Lixisenatide for the Treatment of Type 2 Diabetes. Annals of Pharmacotherapy 51:11, pages 990-999.
Crossref
Crossref
Sujoy Ghosh, A.G. Unnikrishnan, Banshi Saboo, Jothydev Kesavadev, S.R. Aravind, Sarita Bajaj, Rajesh Rajput, Krishna Seshadri, Narsingh Verma, Arvind Gupta, Brij Mohan Makkar, Mihir Saikia, Shailaja Kale, Suresh Damodaran, Ashish Dengra, T.K.M. Eashwar, Anuj Maheshwari, Sharad Pendsey, Sanjeev R. Phatak, Surendra Kumar Sharma, Surya Kumar Singh, A. Ramachandran, Abdul H. Zargar, Shashank R. Joshi & Shaukat M. Sadikot. (2017) Evidence-based recommendations for insulin intensification strategies after basal insulin in type 2 diabetes. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 11, pages S507-S521.
Crossref
Crossref
Pablo F. Mora & Eric L. Johnson. (2017) Cardiovascular Outcome Trials of the Incretin-Based Therapies: What Do We Know So Far?. Endocrine Practice 23:1, pages 89-99.
Crossref
Crossref